GYRE Nilai Total Aset Perusahaan Gyre Therapeutics Inc

GYRE (Gyre Corp) - tandha merek perusahaan

Gyre Therapeutics, Inc. (GYRE) is developing treatments for liver and kidney fibrosis amid minimal political pressure and stable US logistics. The business model relies on massive scalability: following costly research, drug synthesis remains inexpensive, ensuring excess returns. This chart of the price action for total assets, which amount to 186.75, confirms the market valuation and highlights the high value of patents and certification complexities that shut out competitors.

GYRE (Gyre Therapeutics, Inc.) riwayat Total Aset Perusahaan saka 21.02.2024 nganti 01.11.2026

Rincian analitis lan laporan data perusahaan Gyre Corp (GYRE)

- nilai saham lan prakiraan konsensus rega:
Rega bursa gyretx.com|GYRE - Bagan rega target
- data kapitalisasi pasar:
Biji pasar Gyre Therapeutics Corp.|GYRE - Nilai Perusahaan
- statistik nilai buku emiten:
Nilai Akuntansi Saham Gyre Therapeutics|GYRE - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku gyretx.com|GYRE - Aset Agregat Perusahaan
- indikator beban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi Gyre Therapeutics, Inc.|GYRE - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Gyre Therapeutics Corp.|GYRE - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Gyre Therapeutics Corp.|GYRE - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Gyre Therapeutics|Likuiditas cepet gyretx.com
- indikator pendapatan resik lan kelipatan nilai:
GYRE - Bathi resik
Pambiji fundamental:Gyre Therapeutics, Inc.
Produk sing diprodhuksi Gyre Therapeutics, Inc.

To assess the issuer's financial stability, an analysis of total balance sheet assets is utilized, which reverse-calculates the total value of resources via return on assets (ROA). This metric determines the scale of the company's control over capital and liabilities, which for Gyre Therapeutics, Inc. (GYRE) reflects investments in environmentally friendly closed-loop production cycles and the reduction of the carbon footprint during drug development.

Pesaing wigati

Aset Perusahaan arrowheadpharma.com (ARWR)|Aset Agregat Perusahaan Mirum|Dynavax - Nilai Total Aset Perusahaan|Total Aset Perusahaan ABUS|IVA (Inventiva Corp) - Nilai Agregat Aset|Total Aset Perusahaan ASMB (Assembly Biosciences)|Total Aset Perusahaan Galectin Therapeutics, Inc. GALT|GNFT - Aset Agregat Perusahaan|Nilai Agregat Aset DRRX (DURECT Corporation)|aligos.com (ALGS) - Aset Agregat Perusahaan|Gunggung Aset Perusahaan BioVie|GLMD (Galmed Pharmaceuticals Ltd) - Total Aset Perusahaan|Total Aset Perusahaan endrainc.com|Gunggung Aset Perusahaan HEPA (Hepion Pharmaceuticals)